Alexandra (Sandra) Glucksmann

Alexandra (Sandra) Glucksmann is a highly experienced professional who excels in the biotech industry.

With a strong educational background in Molecular Biology and Genetics, Alexandra has honed her expertise through her studies at the Massachusetts Institute of Technology and the University of Chicago.

Throughout her career, Alexandra has held prominent roles in various organizations, including President & CEO, Senior Advisor, Investment Committee Member, Scientific Advisor, Independent Board Member, and Entrepreneur In Residence at well-known biotech companies like Sensorium Therapeutics, Scenic Biotech, Adjuvant Capital, Edity Therapeutics, REGENXBIO Inc., and many more.

Her leadership skills and strategic insights were instrumental during her tenures as President and CEO of Cedilla Therapeutics, COO of Editas Medicine, Chair of the Board of Directors at WEST, and Senior VP of Research and Development at Cerulean Pharma.

Alexandra Glucksmann has a proven track record of success in building and growing biotech companies, leveraging her expertise to drive innovation and team collaboration within the industry.